





# Regional Anesthesia: How Do We Make It Last?




Sarah Tweedy DNP, CRNA, ARNP






I have no conflicts of  
interest and nothing to  
declare



\*Many of these adjuncts are  
considered to be off-label use\*





# Objectives

---


- Understand the basic pharmacology of local anesthetics
- Understand previously used medications and why they are no longer recommended
- Understand currently used medication adjuncts for peripheral nerve blocks
- Understand the future direction of adjuncts for peripheral nerve blocks

# Local Anesthetics: How Do They Work Again?



# Local Anesthetics: How Do They Work Again?

6



# Local Anesthetics: How Do They Work Again?

---

- **Duration of Action**: Determined by \*protein binding and lipid solubility<sup>9</sup>
  - Drugs with high affinity for protein and lipids = firm attachment to those substances
  - Local anesthetic receptor on the neural membrane is composed of protein
  - Site of injection: speed of absorption changes based on location
    - Local anesthetics cause vasodilation (except cocaine and ropivacaine)
- **Onset of Action**: Determined by ionization<sup>9</sup>
  - Charged form will not penetrate membranes well
  - Dreaded pKa (Lower pKa = faster onset; except chloroprocaine which is concentration based)
- **Potency**: Determined by the lipid solubility of the local anesthetic<sup>9</sup>
  - Axolemma and myelin sheath are composed of lipids (i.e. lipid soluble drugs can pass easily through the nerve membrane)
  - Increased lipid solubility correlates with increased protein binding
    - Also correlates with increased likelihood of cardiac toxicity (bupivacaine)

# Local Anesthetics: How Do They Work Again

9

Characteristic	Drug	Common Name	Relative Potency	Onset	Duration (min)
Low potency; short duration of action	Procaine	Novocaine	1	Slow	60-90
	Chloroprocaine	Nesacaine	1	Fast	30-60
Intermediate potency; intermediate - long duration of action	Mepivacaine	Carbocaine	2	Fast	120-240
	Prilocaine	Citanest	2	Fast	120-240
	Lidocaine	Xylocaine	2	Fast	90-200
High potency; long duration of action	Tetracaine	Pontocaine	8	Slow	180-600
	Bupivacaine	Marcaine, Sensorcaine	9	Intermediate	180-600
	Etidocaine	Duranest	6	Fast	180-600
	Ropivacaine	Naropin	10	Slow	180-600

# Local Anesthetics: How Do They Work Again?

Manufacturers' Recommended Single-Injection Max Dose (mg/kg) <sup>9</sup>

Chloroprocaine	11 / (14)
Lidocaine	4 / (7)
Mepivacaine	4 / (7)
Prilocaine	7 / (8.5)
Bupivacaine	2.5 / (3.2)
Etidocaine	6 / (8)
Ropivacaine	3 / (3.5)


\*Drug alone / (drug with epinephrine)



# History of Local Anesthetic Adjuncts

---

- Adenosine
  - No additional benefit<sup>19</sup>
- Dextran
  - Needs high powered studies; currently inconclusive for any benefit<sup>19</sup>
- Fentanyl
  - No benefit when compared to other routes<sup>19</sup>
- Hydromorphone
  - No benefit when compared to other routes<sup>19</sup>
- Ketamine
  - No benefit when compared to other routes<sup>19</sup>
  - Unacceptably high incidence of adverse effects (psychotomimetic)<sup>19</sup>



# History of Local Anesthetic Adjuncts

---

- Midazolam
  - Neurotoxic in animal models<sup>19</sup>
  - Not recommended for use<sup>19</sup>
- Morphine
  - No benefit when compared to other routes<sup>19</sup>
- Neostigmine
  - No benefit<sup>19</sup>
  - Causes adverse side effects that increase with increased doses<sup>19</sup>
  - Neurotoxic when injected perineural<sup>19</sup>
- Sufentanil
  - No benefit when compared to other routes<sup>19</sup>
  - Increased side effect profile<sup>19</sup>

# Current Local Anesthetic Adjuncts

---

- Alpha 2 adrenoreceptor agonists
  - Clonidine
  - Dexmedetomidine
- Buprenorphine
- Epinephrine
- Liposomal Bupivacaine
- Steroid

# Clonidine

---

- Mechanism of action:  $\alpha$ -2 receptor agonist; hyperpolarization of nucleotide gated cation channels<sup>19</sup>
- Dosing: 0.5 $\mu$ g/kg (max 150 $\mu$ g)<sup>19</sup>
- Wide range of results<sup>19</sup>
  - One meta analysis showed duration was prolonged by 2 hours
  - Best used with intermediate acting local anesthetics
  - Upper extremity blocks had more success than lower extremity blocks
  - Adverse effects increased with increased doses
- More extensive research needs to be completed before routine use is recommended<sup>19</sup>

# Dexmedetomidine

---

- Mechanism of action:  $\alpha$ -2 receptor agonist (7 times more selective than clonidine); hyperpolarization of nucleotide gated cation channels<sup>19</sup>
- Dosing: 1-2 $\mu$ g/kg<sup>13,19</sup>
  - Lower dose = less side effects
- Increased duration of motor block, and prolonged time to first request for analgesia for brachial plexus blocks<sup>19</sup>
- Increased duration of sensory block by 3 hours and reduction of pain scores for 4 hours<sup>18</sup>
- Low incidence of adverse effects, can see hypotension/bradycardia as seen with IV administration<sup>19</sup>

# Buprenorphine

---

- Mechanism of action: decreased potassium conduction and increased calcium conduction; inhibits release of Substance P<sup>14</sup>
  - Substance P is a proinflammatory polypeptide secreted by nerves and inflammatory cells that is thought to be involved in the synaptic transmission of pain
- Dosing: 0.3mg or 0.3µg/kg<sup>19</sup>
- Duration of action prolonged 1.5- to 3-fold for brachial plexus and sciatic nerve blocks<sup>9, 14, 19</sup>
  - Some studies included epinephrine + buprenorphine
  - Perineural addition extended block longer than IM
  - Increased risk of PONV, no other adverse effects increased
    - Recommended to provide polymodal antiemetics

# Epinephrine


---

- Proposed mechanism of action: constricts vessels in surrounding area<sup>19</sup>
  - Some antinociceptive properties through  $\alpha$ -2 agonism
- Dosing: 0.5-1 $\mu$ g/kg or 5-10 $\mu$ g/mL<sup>19</sup>
- Does not prolong the duration to the same extent with all locals<sup>19</sup>
  - Best with short and intermediate acting local anesthetics
  - Recent study showed no longer than 60 minutes extra<sup>21</sup>
- Can increase the risk for neurotoxicity<sup>3</sup>
  - Current recommendations are against use of epinephrine unless ultrasound is unavailable or tip of needle is not visualized

# Liposomal Bupivacaine

Bupivacaine encapsulated in DepoFoam

11






# Liposomal Bupivacaine

- Mechanism of action: microscopic lipid vesicles ranging in size from 0.02-40  $\mu\text{m}$  act as reservoirs for drugs with low bioavailability<sup>19</sup>
- FDA approved for hemorrhoidectomy, bunionectomy, fascial plane blocks and recently interscalene nerve blocks<sup>11</sup>
  - Dentistry as well
- Mixed results of efficacy depending on the study you read<sup>11</sup>
  - Some state no statistical difference in outcome
  - Some state 1st day specifically a reduction in opioid use
  - Some state up to 72 hours of relief
  - Detected in plasma up to 96 (infiltration)-120 (interscalene) hours after injection
- Potential side effects<sup>11</sup>
  - Avoid additional local anesthetic for 72 hours\*
  - Nausea, vomiting or constipation
  - Always risk of local anesthetic side effects

# Liposomal Bupivacaine



# Liposomal Bupivacaine

## Administration:

- Comes in a 10 or 20mL vial at 1.3% concentration (max dose is 20mL or 266mg for infiltration; 10mL or 133mg for brachial plexus blocks)<sup>11</sup>
- Not verified for use in <18yoa<sup>11</sup>
- Dilution with sterile saline up to 300mL<sup>11</sup>
  - May also *admix* bupivacaine HCl- do not exceed 1:2 (bupi HCL:liposomal bupi)
    - Example: 0.5% Bupi HCl: max 133mg (26mL) with 20mL liposomal bupivacaine
  - Wait at least 20 minutes after lidocaine infiltration to administer
- Do not mix liposomal bupivacaine with anything except the above mentioned<sup>11</sup>
  - Possibility of reducing the efficacy of DepoFoam to encapsulate bupivacaine

# Steroid (Dexamethasone)

---

- Mechanism of action: Current theory- local action on nerve fibers<sup>19</sup>
  - Not the same as it's anti-inflammatory effect
- Dosing: 4, 8, & 10mg all used; no dose-response relationship noted<sup>7</sup>
- 37% increase in prolongation of upper and lower extremity blocks when used with ropivacaine<sup>5</sup>
  - Decreased pain for 24 hours
- A meta-analysis showed reduction of pain scores at 2, 6 and 12 hours and reduced pain medication intake for 24 hours<sup>4</sup>
- Some studies have shown no statistical difference between intravenous and perineural administration<sup>8</sup>
  - Cochrane review showed perineural prolonged sensory block 3 more hours; no difference in pain intensity/pain medications taken<sup>15</sup>

# Future Local Anesthetic Adjuncts

---

- Bupivacaine-collagen implant
- Liposomal adjuncts
- Magnesium
- SABER-bupivacaine
- Tramadol - old & new



# Bupivacaine-Collagen Implant

---

- Mechanism of Action: Collagen matrix that is biodegradable and fully resorbable, impregnated with bupivacaine that is released as the collagen is degraded<sup>11</sup>
- Dosing: Currently varying concentrations<sup>11</sup>
  - Bi-phasic peaks such as that with liposomal bupivacaine
  - Initial research shows 30 minutes to 20 hours
- One study showed decreased pain scores at 24 & 48 hours with no change in opioid intake and another showed no change in pain scores but opioid intake was reduced<sup>11</sup>
  - More studies needed!
- Side effects: Constipation, nausea & headache<sup>11</sup>

# Liposomal Adjuncts

---

- Duration of Action: Extended duration of action due to liposomes surrounding medication<sup>16</sup>
- Animal studies showing positive results for both liposomal dexamethasone and liposomal dexmedetomidine when added with liposomal bupivacaine<sup>16</sup>
  - Increased block 2.9-fold
  - Duration of time increased 16.2 +/- 3.5 hours
    - Single adjunct addition extended 8-10 hours
  - Decreased tissue inflammation as well
- \*Addition of unencapsulated adjuvants prolong duration by 25 +/- 6.3 hours<sup>16</sup>
  - Accompanied with systemic side effects

# Magnesium

---

- Mechanism of action: NMDA receptor antagonist, voltage-gated calcium channel inhibition<sup>19</sup>
- Doubled the analgesic effect of lidocaine interscalene block with 500mg MgSO<sub>4</sub> in one study<sup>19</sup>
  - Has been shown to add ~2 hours to bupivacaine/epinephrine ISB
  - \*Study completed outside of U.S.<sup>1</sup>
- Lack of well defined neurotoxicity studies; therefore, it is currently not recommended for routine use<sup>19</sup>
- Side effects: bradycardia, hypotension, sedation, headache<sup>19</sup>



# SABER-Bupivacaine

---

- Sucrose Acetate Isobutyrate Extended Release-Bupivacaine<sup>11</sup>
- Mechanism of Action: bioerodable injectable depot system (able to deliver drugs over days to 3 months)<sup>11</sup>
  - Linear pharmacokinetics; location of block can disrupt how long medication lasts
- One study showed this medication decreased pain up to 3 days<sup>11</sup>
- Again, more studies necessary before approval<sup>11</sup>

# Tramadol

---

- Proposed mechanism of action: some inhibition of voltage gated potassium and sodium channels<sup>10</sup>
- Previously contradictory results<sup>17</sup>
- 2017 meta-analysis of brachial plexus blocks +/- tramadol<sup>17</sup>
  - 100mg prolonged sensory block by 61.5 minutes for axillary block (not ISB or SCB)
  - 100mg prolonged motor block by 65.6 minutes
  - 100mg prolonged analgesia by 125.5 minutes
  - Did not increase chance of adverse effects
- Likely more research to come- not yet recommended for routine use


# LAST but not least....

---

Know your signs/symptoms of Local Anesthetic Systemic Toxicity (LAST)<sup>12</sup>:

- Vertigo
- Tinnitus
- Ominous Feelings
- Circumoral numbness
  - Garrulousness
  - Tremors
- Myoclonic Jerks
  - Convulsions
  - Coma
- Cardiovascular Collapse

# Treatment of LAST



# Any Questions?



**COCAINE**  
**TOOTHACHE DROPS**  
Instantaneous Cure!  
**PRICE 15 CENTS.**  
Prepared by the  
**LLOYD MANUFACTURING CO.**  
219 HUDSON AVE., ALBANY, N. Y.  
For sale by all Druggists.  
(Registered March 1885.) See other side.

# References

1. Abdelfatah, A., & Elshaer, A. (2014). The effect of adding magnesium sulfate to lidocaine in an interscalene plexus block for shoulder arthroscopic acromioplasty. *Ain-Shams Journal of Anaesthesiology*. <https://doi.org/10.4103/1687-7934.128416>
2. Beelew, J.W., Michlovitz, S.L., & Nolan, T.P. (2016). *Michlovitz's modalities for therapeutic intervention* (6th ed.). Philadelphia, PA: F.A. Davis Company
3. Brummett, C. M., & Williams, B. A. (2011). Additives to Local Anesthetics for Peripheral Nerve Blockade. *International Anesthesiology Clinics*. <https://doi.org/10.1097/aia.0b013e31820e4a49>
4. Chen, Q., An, R., Zhou, J., & Yang, B. (2018). Clinical analgesic efficacy of dexamethasone as a local anesthetic adjuvant for transversus abdominis plane (TAP) block: A meta-analysis. *PloS One*. <https://doi.org/10.1371/journal.pone.0198923>
5. Emelife, P. I., Eng, M. R., Menard, B. L., Myers, A. S., Cornett, E. M., Urman, R. D., & Kaye, A. D. (2018). Adjunct medications for peripheral and neuraxial anesthesia. *Best Practice and Research: Clinical Anaesthesiology*. <https://doi.org/10.1016/j.bpa.2018.06.011>
6. Gadsen, A. & Jones, D. (2017). *Anesthesiology self-assessment and board review: BASIC examination*. McGraw Hill Education.
7. Heesen, M., Klimek, M., Imberger, G., Hoeks, S. E., Rossaint, R., & Straube, S. (2018). Co-administration of dexamethasone with peripheral nerve block: intravenous vs perineural application: systematic review, meta-analysis, meta-regression and trial-sequential analysis. *British Journal of Anaesthesia*. <https://doi.org/10.1016/j.bja.2017.11.062>
8. Kahn, R. L., Cheng, J., Gadulov, Y., Fields, K. G., YaDeau, J. T., & Gulotta, L. V. (2018). Perineural Low-Dose Dexamethasone Prolongs Interscalene Block Analgesia With Bupivacaine Compared With Systemic Dexamethasone: A Randomized Trial. *Regional Anesthesia and Pain Medicine*, 43(6), 572-579. doi: 10.1097/aap.0000000000000817
9. Kirksey, M. A., Haskins, S. C., Cheng, J., & Liu, S. S. (2015). Local anesthetic peripheral nerve block adjuvants for prolongation of analgesia: A systematic qualitative review. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0137312>
10. Nagelhout, J. & Plaus, K. (2010). *Nurse Anesthesia* (4th ed.). St. Louis, MO: Saunders Elsevier.
11. New York School of Regional Anesthesia. (2019). Controlled-Release Local Anesthetics. Retrieved from <https://www.nysora.com/foundations-of-regional-anesthesia/pharmacology/controlled-release-local-anesthetics/>

# References

12. New York School of Regional Anesthesia. (2019). Local Anesthetic Systemic Toxicity. Retrieved from <https://www.nysora.com/foundations-of-regional-anesthesia/complications/local-anesthetic-systemic-toxicity/>
13. Packiasabapathy, S., Arora, M., Mohan, V., Yadav, C., Prasad, G., Batra, R., & Kashyap, L. (2017). Effect of dexmedetomidine as an adjuvant to bupivacaine in femoral nerve block for perioperative analgesia in patients undergoing total knee replacement arthroplasty: A dose–response study. *Saudi Journal of Anaesthesia*. [https://doi.org/10.4103/sja.sja\\_624\\_16](https://doi.org/10.4103/sja.sja_624_16)
14. Patil, S., Debata, D., Doshi, C., Vyas, V., & Sinha, S. (2015). Effect of buprenorphine as an adjunct with plain local anesthetic solution in supraclavicular brachial plexus block on quality and duration of postoperative analgesia. *Journal of Anaesthesiology, Clinical Pharmacology*. <https://doi.org/10.4103/0970-9185.169072>
15. Pehora, C., Pearson, A. M. E., Kaushal, A., Crawford, M. W., & Johnston, B. (2017). Dexamethasone as an adjuvant to peripheral nerve block. *Cochrane Database of Systematic Reviews*. <https://doi.org/10.1002/14651858.CD011770.pub2>
16. Rwei, A. Y., Sherburne, R. T., Zurakowski, D., Wang, B., & Kohane, D. S. (2018). Prolonged duration local anesthesia using liposomal bupivacaine combined with liposomal dexamethasone and dexmedetomidine. *Anesthesia and Analgesia*. <https://doi.org/10.1213/ANE.0000000000002719>
17. Shin, H. W., Ju, B. J., Jang, Y. K., You, H. S., Kang, H., & Park, J. Y. (2017). Effect of tramadol as an adjuvant to local anesthetics for brachial plexus block: A systematic review and meta-analysis. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0184649>
18. Sun, Q., Liu, S., Wu, H., Ma, H., Liu, W., Fang, M., . . . Pan, Z. (2018). Dexmedetomidine as an Adjuvant to Local Anesthetics in Transversus Abdominis Plane Block: A Systematic Review and Meta-analysis. *Clinical Journal of Pain*. doi: 10.1097/ajp.0000000000000671
19. Swain, A., Nag, D. S., Sahu, S., & Samaddar, D. P. (2017). Adjuvants to local anesthetics: Current understanding and future trends. *World Journal of Clinical Cases*. <https://doi.org/10.12998/wjcc.v5.i8.307>
20. Tschopp, C., Tramèr, M. R., Schneider, A., Zaarour, M., & Elia, N. (2018). Benefit and harm of adding epinephrine to a local anesthetic for neuraxial and locoregional anesthesia: A meta-analysis of randomized controlled trials with trial sequential analyses. *Anesthesia and Analgesia*. <https://doi.org/10.1213/ANE.0000000000003417>
21. Trevor, A., Katzung, B., Masters, S., & Knudering-Hall, M. (2012). *Katzung & Trevor's Pharmacology Examination and Board Review* (10th ed.). McGraw Hill Education.